Abstract
During the COVID-19 pandemic, numerous SARS-CoV-2 infections remained undetected. Serological testing could potentially aid their identification. We combined results from routine monthly nose and throat swabs, and self-reported positive swab tests, from a UK household survey, linked to national swab testing programme data from England and Wales, together with Nucleocapsid (N-) antibody trajectories clustered using a longitudinal variation of K-means to estimate the number of infections undetected by either approach (N=185,646). After combining N-antibody (hypothetical) infections with swab-positivity, we estimated that 7.4% of all true infections would have remained undetected, 25.8% by swab-positivity-only and 28.6% by trajectory-based N-antibody classifications only. Congruence with swab-positivity was much poorer using a fixed threshold to define N-antibody infections. Additionally, using multivariable logistic regression N-antibody seroconversion was more likely as age increased between 30 and 60 years, in non-white participants, those less (recently/frequently) vaccinated, for lower Ct values in the range above 30, in symptomatic and Delta (vs BA.1) infections. Comparing swab-positivity data sources showed that routine monthly swabs were not sufficient to detect infections by swab-positivity only and incorporating national testing programme/self-reported data substantially increased detection rates. Overall, whilst N-antibody serosurveillance can identify infections undetected by swab-positivity, optimal use requires trajectory-based analysis.
Competing Interest Statement
This study was funded by the UK Health Security Agency and the Department of Health and Social Care with in-kind support from the Welsh Government, the Department of Health on behalf of the Northern Ireland Government and the Scottish Government. ASW and KBP are supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with the UK Health Security Agency (UK HSA) (NIHR200915). ASW is also supported by the NIHR Oxford Biomedical Research Centre. KBP is also supported by the Huo Family Foundation. There are no other conflicts of interest.
Clinical Protocols
https://www.ndm.ox.ac.uk/covid-19/covid-19-infection-survey/protocol-and-information-sheets
Funding Statement
This study was funded by the UK Health Security Agency and the Department of Health and Social Care with in-kind support from the Welsh Government, the Department of Health on behalf of the Northern Ireland Government and the Scottish Government. ASW and KBP are supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with the UK Health Security Agency (UK HSA) (NIHR200915). ASW is also supported by the NIHR Oxford Biomedical Research Centre. KBP is also supported by the Huo Family Foundation. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The South Central Berkshire B Research Ethics Committee (20/SC/0195) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
De-identified study data are available for access by accredited researchers in the ONS Secure Research Service (SRS) for accredited research purposes under part 5, chapter 5 of the Digital Economy Act 2017. Individuals can apply to be an accredited researcher using the short form on https://researchaccreditationservice.ons.gov.uk/ons/ONS_registration.ofml. Accreditation requires completion of a short free course on accessing the SRS. To request access to data in the SRS, researchers must submit a research project application for accreditation in the Research Accreditation Service (RAS). Research project applications are considered by the project team and the Research Accreditation Panel (RAP) established by the UK Statistics Authority at regular meetings. Project application example guidance and an exemplar of a research project application are available. A complete record of accredited researchers and their projects is published on the UK Statistics Authority website to ensure transparency of access to research data. For further information about accreditation, contact Research.Support{at}ons.gov.uk or visit the SRS website.
